Literature DB >> 2661013

5-Hydroxytryptamine and its putative aetiological involvement in migraine.

J W Lance1, G A Lambert, P J Goadsby, A S Zagami.   

Abstract

5-Hydroxytryptamine (5-HT, serotonin) is thought to play a part in the pathophysiology of migraine because platelet content of 5-HT in cubital and external jugular veins is reduced during migraine headache. Moreover migraine headache is precipitated by intramuscular injection of reserpine, which releases 5-HT from body stores, is relieved by the intravenous infusion of serotonin, and is prevented by the regular administration of medications that act on 5-HT receptors. Whether the peripheral action of 5-HT on cerebral and extracranial vessels or its central action as a neurotransmitter involved in bulbocortical and pain control pathways is of greater importance in the mechanism of migraine remains an open question. Increasing knowledge of the varieties of 5-HT receptor and the development of pharmacological agents that act specifically on certain receptors should give greater insight into the cause of migraine and increase the efficacy of treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661013     DOI: 10.1111/J.1468-2982.1989.TB00067.X

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

1.  Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system.

Authors:  O Spigset
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

Review 2.  5-HT3 receptor antagonists and migraine therapy.

Authors:  M D Ferrari
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

Review 3.  Rationale for the use of 5-HT1-like agonists in the treatment of migraine.

Authors:  W Feniuk; P P Humphrey; M J Perren; H E Connor; E T Whalley
Journal:  J Neurol       Date:  1991       Impact factor: 4.849

4.  Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders.

Authors:  I Jansen; P Tfelt-Hansen; L Edvinsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  [Clinical aspects of pathophysiological mechanisms in migraine.].

Authors:  K H Grotemeyer; I W Husstedt; H P Schlake
Journal:  Schmerz       Date:  1989-12       Impact factor: 1.107

Review 6.  5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives.

Authors:  J R Fozard; H O Kalkman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.